COVID-19 spike variants antigen Recombinant 2019-nCoV(SARS-CoV-2) (UK variant B.1.1.7 lineage Spike Protein RBD-N501Y mutant (SRBD-N501Y, C-HisTag)

Order information

Package	Catalog No.	Price(In USD)	Qty (Quantity)	Sum(In USD)
1mg	GMP-V-2019nCoV-Smu-002-1mg	5990
10mg	GMP-V-2019nCoV-Smu-002-10mg	38790
100mg	GMP-V-2019nCoV-Smu-002-100mg	258000
≥100mg	GMP-V-2019nCoV-Smu-002-xmg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Accession Number	QHD43415.1
Expression platform	2019-nCoV(SARS-CoV-2, SARS2-coronavirus)
Isotypes	Mamamlian (human cell)
Tag	C-His
Products description	Recombinant 2019-nCoV(SARS-CoV-2)-UK variant B.1.1.7 lineage receptor binding domain (RBD) from the Spike Protein (S protein) with N501Y mutation was expressed in mammanlian cell (human cells) expression system with 6 HIS tag at the C-terminus.
Bioactivity validation	ACE2 binding; Immunogen in Sandwich Elisa, lateral-flow tests,and other immunoassays;
Purity	Purity: ≥95% (SDS-PAGE)
Application	Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies. Immunogen in Elisa,lateral-flow tests,and other immunoassays; Standard substance The antigen can also be used in drug discovery including antibody screening and lead compound candidates assay.
predicted Molecular Mass	35kDa
Formulation	Lyophilized from sterile PBS, PH 7.4
Storage	Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

COVID-19 recombinant SARS-CoV2 (2019 nCoV coronavirus) antigen:
Recombinant 2019-nCoV(SARS-CoV-2) (UK variant B.1.1.7 lineage) Spike Protein RBD-N501Y mutant (SRBD-N501Y,C-HisTag)

Suitable for variants of Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19vaccines and therapeutic antibodies.

Products & Information Collection of SARS-CoV-2 (2019nCOV)spike-N501Y mutation

The world is in midst of the COVID-19 pandemic caused by SARS-CoV-2 (2019nCoV) infection. The Spike protein (S-protein) of SARS-CoV-2 (2019nCoV) mediates receptor (ACE2) binding and cell entry and is the dominant target of the immune system. Most mutations and deletions of SARS-CoV-2 occur in the coronavirus spike protein. Spike position N501, one of the key contact residues in the receptor-binding domain (RBD), and experimental data suggest mutation N501Y can increase ACE2 receptor affinity (Starr et al. 2020). N501Y has also been associated with increased infectivity and virulence in a mouse model (Gu et al. 2020).

Recently a novel SARS-COV-2 (2019nCOV) lineage, the B.1.1.7 lineage, with serials of site mutation, shows stronger infection ability in the UK. In SARS-COV-2 B.1.1.7 lineage, most mutations and deletions occur in the coronavirus spike protein. These mutantions also include SARS-CoV-2 spike- mutation. N501Y mutation is also found in the South Africa 501Y.V2 lineage(B.1.351).

GeneMedi pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) Spike-N501Y mutation

Taking responsibility to help accelerate the COVID-19 vaccine and therapeutic antibody discovery and development, GeneMedi had developed the pseudotype virus (pseudovirus) of SARS-COV-2 (2019nCOV) spike-N501Y mutation, which will meet the evaluation of the efficacy of COVID-19 vaccines and therapeutic antibodies.

Cat No.	Antigen Name of 2019-nCoV(SARS-CoV-2)	Isotypes	Order
GMP-V-2019nCoV-Smu-002	Recombinant 2019-nCoV(SARS-CoV-2) (UK variant B.1.1.7 lineage) Spike Protein RBD-N501Y mutant (SRBD-N501Y, C-HisTag)	Mammalian (human cell)
GMP-H-ACE2001	Recombinant human solubale ACE2 protein (soluble hACE2,extracellular hACE2, C-His)	Mammalian (human cell)
GMP-H-ACE2002	Recombinant human solubale ACE2 protein (soluble hACE2,extracellular hACE2, C-His)	Mammalian (human cell)

SARS-COV-2 (2019nCOV) variant-N501Y mutation of Spike protein & ACE2 competition binding assay for efficacy evaluation of COVID-19 vaccines and therapeutic antibodies

GeneMedi codon-optimized spike mammalian expression vector for SARS-COV-2 (2019nCOV) spike-N501Y mutation

GeneMedi designed a mammalian expression codon-optimized spike mutation/deletion variant vector for COVID-19 SARS-COV-2 (2019nCOV) spike-N501Y mutation

Reference:
1 Gu, Hongjing, Qi Chen, Guan Yang, Lei He, Hang Fan, Yong-Qiang Deng, Yanxiao Wang, et al. 2020. “Adaptation of SARS-CoV-2 in BALB/c Mice for Testing Vaccine Efficacy.” Science 369 (6511): 1603–7.
2 Starr, Tyler N., Allison J. Greaney, Sarah K. Hilton, Daniel Ellis, Katharine H. D. Crawford, Adam S. Dingens, Mary Jane Navarro, et al. 2020. “Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding.” Cell 182 (5): 1295–1310.e20.